Delcath stock.

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded in August 1988 and is headquartered in New York, NY. DCTH - Delcath Systems Inc - Stock screener for investors and traders, financial visualizations.According to 4 analysts, the average rating for DCTH stock is "Strong Buy." The 12-month stock price forecast is $18.0, which is an increase of 542.86% from the latest price.Oncology-focused healthcare equipment maker Delcath Systems ( NASDAQ: DCTH) added ~66% pre-market Tuesday after announcing the FDA approval of its Hepzato Kit device as a treatment for a type of ...NEW YORK, March 29, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic ...

DELCATH SYSTEMS, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) ... 2006, the day before Laddcap commenced its consent solicitation, the market value per share of common stock has increased by approximately 469%. Delcath's Board of Directors and management …Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. We are a specialty pharmaceutical and medical device company developing our proprietary product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). May 12, 2023 · Delcath is in the process of completing its customary quarter-end close and review procedures, including certain valuation work associated with the issuance of warrants and preferred stock in ...

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. With the latest financial year loss of ...

Based on short-term price targets offered by four analysts, the average price target for Delcath Systems, Inc. comes to $17.00. The forecasts range from a low of $13.00 to a high of $21.00. The ...Stock control is important because it prevents retailers from running out of products, according to the Houston Chronicle. Stock control also helps retailers keep track of goods that may have been lost or stolen.0001564590-15-006231.txt : 20150805 0001564590-15-006231.hdr.sgml : 20150805 20150805161855 ACCESSION NUMBER: 0001564590-15-006231 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENTView Our Latest Stock Analysis on DCTH. Delcath Systems Price Performance. NASDAQ DCTH opened at $2.45 on Thursday. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.30 and a quick ratio of 1.53. The stock’s fifty day moving average price is $3.62 and its 200 day moving average price is $4.93.Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. With the latest financial year loss of ...

Delcath Systems to raise $5M in stock and warrants offering SA News Mon, Jul. 18, 2022. Delcath Systems GAAP EPS of -$1.00 misses by $0.12, revenue of $0.38M beats by $0.07M

Delcath Systems, Inc. v. Iroquois Capital Investment Group Llc, Iroquois Master Fund Ltd., L1 Capital Global Opportunities Master Fund, Firstfire Global Opportunities Fund Llc; AFFIDAVIT-OR-AFFIRMATION-IN-SUPPORT-OF-PROPOSED-OSC-EXPARTE-APP-Motion-001-Affidavit-of-Barbra-C-Keck

Stock Exchange NASDAQ Ticker Symbol DCTH Full Company Profile Financial Performance In 2022, DCTH's revenue was $2.72 million, a decrease of …Delcath's stock price increased 34 percent on that news. There are no records showing that any Delcath officers or directors received options or bought stock in the weeks before the Fast Track ...(4) To adopt an amendment to Delcath’s 2009 Stock Incentive Plan, effective upon approval by our stockholders at the Annual Meeting, (i) to increase the number of our shares of common stock with respect to which grants may be made under the plan by 1,700,000 shares to 3,206,250 shares, (ii) eliminate provisions that include shares withheld from …Dec 5, 2022 · Data Provided by Thomson Reuters. Delcath Systems, Inc. (NASDAQ-DCTH) is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. See all of Delcaths investors and understand how they are helping revolutionize how cancer is treated. Delcath Systems Inc. Watch list NEW Set a price target alert Premarket Last Updated: Nov 6, 2023 9:17 a.m. EST Delayed quote $ 3.1000 -0.02 -0.64% Before Hours Volume: 344 Advanced Charting... 27 thg 3, 2023 ... These are the most under-owned large-cap tech stocks - MS. Today, 11:40 AM21 Comments · See More ». About DCTH. Symbol, Last Price, % Chg. DCTH.

May 17, 2022 · Company Overview: Delcath Systems Inc. owns a medical device approved in Europe and a drug-device candidate pursuing approval in the U.S. The company is based in the Big Apple. Currently the ... Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The …Delcath will issue and sell 1,448,889 shares of its common stock (the "Common Stock") at a price per share of $2.90, or, in lieu of shares of Common Stock, 692,042 pre-funded warrants to purchase ...0001193125-15-375676.txt : 20151112 0001193125-15-375676.hdr.sgml : 20151112 20151112161435 accession number: 0001193125-15-375676 conformed submission type: 424b3 public document count: 1 filed as of date: 20151112 date as of change: 20151112 filer: company data: company conformed name: delcath systems, inc. central index key: …Mr Michel DCTH stock SEC Form 4 insiders trading. Mr has made over 25 trades of the Delcath Systems stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 19,646 units of DCTH stock worth $95,087 on 29 March 2023.. The largest trade he's ever made was exercising 112,481 units of Delcath …

Delcath Systems, Inc. DCTH shares soared 6.6% in the last trading session to close at $11.72. The move was backed by solid volume with far more shares changing hands than in a normal session.

15.2%. 10% least volatile stocks in US Market. 2.9%. Stable Share Price: DCTH is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week. Volatility Over Time: DCTH's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.DCTH | 1 hour ago. NEW YORK, Nov. 15, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee ...Delcath Systems, Inc. DCTH shares soared 6.6% in the last trading session to close at $11.72. The move was backed by solid volume with far more shares changing hands than in a normal session.Track Delcath Systems Inc (DCTH) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Delcath Systems, Inc. (NASDAQ:DCTH) released its quarterly earnings results on Monday, November, 13th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $0.10. The business earned $0.43 million during the quarter, compared to the consensus estimate of $0.68 million.Delcath Systems to raise $5M in stock and warrants offering SA News Mon, Jul. 18, 2022 Delcath Systems GAAP EPS of -$1.00 misses by $0.12, revenue of $0.38M beats by $0.07MDividends. A high-level overview of Delcath Systems, Inc. (DCTH) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

The following institutional investors have sold Delcath Systems stock in the last 24 months: Kent Lake Capital LLC ($94.47K), and Cibc World Market Inc. ($5K). How much institutional selling is happening at Delcath Systems? Institutional investors have sold a total of 99,468 shares in the last 24 months. This volume of shares sold represents ...

DCTH Stock 12 Months Forecast. $18.33. (536.46% Upside) Based on 3 Wall Street analysts offering 12 month price targets for Delcath Systems in the last 3 months. The average price target is $18.33 with a high forecast of $21.00 and a low forecast of $16.00. The average price target represents a 536.46% change from the last price of $2.88.

View the latest Delcath Systems Inc. (DCTH) stock price, news, historical charts, analyst ratings and financial information from WSJ.Insiders trading at Delcath Systems. Over the last 4 years, insiders at Delcath Systems have traded over $0 worth of Delcath Systems stock and bought 1,064,320 units worth $8,436,426 . The most active insiders traders include Marco Taglietti, Gerard J Michel, and Advisors, Inc. Rosalind.On average, Delcath Systems executives …united states. securities and exchange commission. schedule 14a (rule 14a-101) information required in proxy statementAt one point, Delcath's stock was delisted from NASDAQ and share price was trading at 2 cents on OTC exchange before numerous reverse splits. Investors have written off Delcath and thought it was ...Company Overview: Delcath Systems Inc. owns a medical device approved in Europe and a drug-device candidate pursuing approval in the U.S. The company is based in the Big Apple. Currently the ...1w 1m 6m ytd 1y 3y 5y max Mountain-Chart Compare with Compare with up to 5 Stocks On Friday 11/24/2023 the closing price of the Delcath Systems Inc …Delcath's stock price increased 34 percent on that news. There are no records showing that any Delcath officers or directors received options or bought stock in the weeks before the Fast Track ...Delcath Systems Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions.Source: Kantar Media. View the latest Delcath Systems Inc. (DCTH) stock price, news, historical charts, analyst ratings and financial information from WSJ.1w 1m 6m ytd 1y 3y 5y max Mountain-Chart Compare with Compare with up to 5 Stocks On Friday 11/24/2023 the closing price of the Delcath Systems Inc …DCTH : 2.70 (+10.20%) Delcath Systems to Participate in the Lytham Partners Fall 2023 Investor Conference PR Newswire - Tue Oct 10, 7:30AM CDT. /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

Oncology-focused healthcare equipment maker Delcath Systems (DCTH) announced Monday that the FDA accepted its resubmitted new drug application ((NDA)) for the HEPZATO Kit for...Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announces that ...Mr Michel DCTH stock SEC Form 4 insiders trading. Mr has made over 25 trades of the Delcath Systems stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 19,646 units of DCTH stock worth $95,087 on 29 March 2023.. The largest trade he's ever made was exercising 112,481 units of Delcath …Discover historical prices for DCTH stock on Yahoo Finance. View daily, weekly or monthly format back to when Delcath Systems, Inc. stock was issued. Instagram:https://instagram. etf for oil stockstransocean inc stockis facet legitprecious metal etfs Delcath Systems, Inc. v. Iroquois Capital Investment Group Llc, Iroquois Master Fund Ltd., L1 Capital Global Opportunities Master Fund, Firstfire Global Opportunities Fund Llc; AFFIDAVIT-OR-AFFIRMATION-IN-SUPPORT-OF-PROPOSED-OSC-EXPARTE-APP-Motion-001-Affidavit-of-Barbra-C-KeckNov 28, 2023 · Delcath Systems (DCTH) Company Description: Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. best dental discount plans texasdividend calendar app Delcath is in the process of completing its customary quarter-end close and review procedures, including certain valuation work associated with the issuance of warrants and preferred stock in ...Delcath Systems, Inc. Common Stock (DCTH) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. insider stock buys Insider Buying: Delcath Systems, Inc. (NASDAQ:DCTH) COO Purchases $49,897.20 in Stock Ticker Report • about 1 month ago Delcath Systems, Inc. (NASDAQ:DCTH Get Free Report) COO John Purpura acquired 14,505 shares of the stock in a transaction dated Friday, October 13th. 0001564590-16-028959.txt : 20161110 0001564590-16-028959.hdr.sgml : 20161110 0001564590-16-028959.hdr.sgml : 20161110Nov 18, 2023 · View Our Latest Stock Analysis on DCTH. Delcath Systems Price Performance. NASDAQ DCTH opened at $2.45 on Thursday. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.30 and a quick ratio of 1.53. The stock’s fifty day moving average price is $3.62 and its 200 day moving average price is $4.93.